1) benign end-stage liver disease
良性终末期肝病
1.
Pretransplantation MELD score predicts short-term survival of patients with benign end-stage liver disease post-liver transplantation;
MELD评分预测良性终末期肝病肝移植术后短期生存率的初步研究
2) End-stage liver disease
终末期肝病
1.
Advances in the study on malnutrition in end-stage liver disease
终末期肝病营养不良的研究进展
3) hepatitis B related end-stage liver disease
乙肝相关性终末期肝病
1.
Methods:To test the levels of 100 cases of hepatitis B related end-stage liver disease(31 cases of liver cancer,34 cases of liver cirrhosis,35 cases of chronic severe hepatitis) patients on admission CMV-pp65,HBV-DNA and white blood cells.
目的:调查乙肝相关性终末期肝病患者活动性巨细胞病毒(cytomegalovirus,CMV)感染情况,研究活动性CMV感染与HBV-DNA及白细胞的关系,探讨CMV-IgM抗体诊断活动性CMV感染的意义,为临床活动性CMV感染诊疗提供参考。
4) end-stage liver disease secondary to hepatitis B
乙肝终末期肝病
1.
The outcome of liver transplantation for end-stage liver disease secondary to hepatitis B is remarkably impacted by recurrent infection and subsequent allograft failure.
乙肝终末期肝病患者肝脏移植术后乙肝复发是影响患者长期存活的重要因素。
5) model for end-stage liver disease
终末期肝病模型
1.
A retrospective analysis of prognosis on patients with severe hepatitis using the model for end-stage liver disease;
重型肝炎的终末期肝病模型预后回顾性分析
2.
Objective To investigate the predictive value of model for end-stage liver disease(MELD) for the evaluation of the short-time outcome of patients underwent liver transplantation.
目的探讨术前终末期肝病模型(model for end-stage liver disease,MELD)评分在肝移植治疗终末期肝病早期预后中的预测价值。
6) Model for end-stage liver disease(MELD)
终末期肝病模型
1.
Objective: To investigate the relationship between the model for end-stage liver disease(MELD) and Child-Turcotte-Pugh(CTP) scoring,and the prognosis of patients with decompensated liver cirrhosis.
目的:研究终末期肝病模型(MELD)与Child-Turcotte-Pugh(CTP)评分系统和肝硬化失代偿期患者短期(3个月)预后的关系。
补充资料：肝病
肝病
医案著作。李普等编。本书汇集作者等14人治疗肝脏疾病验案170例，分急性肝炎、重症肝炎、慢性肝炎、肝硬化、肝硬化合并腹水和其他6部分。1980年由河南人民出版社出版。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条